A human cell study demonstrated that astragalus reduced oxidative damage to kidney cells. Pretreatment of animal kidney cells with astragalus before use of chemotherapy on these cells reduced the toxic effect of the chemotherapy without reducing its effectiveness. Astragalus also slowed renal tumor progression in animal studies.
Suggested dose: Use of standardized extract: 250-500 mg, 3-4 times per day standardized to 0.4% 4-hydroxy-3-methoxy isoflavones; Powdered root: 250 – 500 mg, 3-4 times per day; Tincture (1:5) in 30% ethanol: 20-60 drops, 3 times per day.
Cat’s claw has historically been used for decades to boost the immune system in the genitourinary systems. As a renal cancer therapy, it may prove useful as it has anti-inflammatory effects in cancer cell lines studies
Suggested dose: 250-350 mg per day of the ethanolic extract.
Human cell studies showed that co-treatment with berberine extract and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced cell death in human renal cancer cells. It has also demonstrated positive effects in animal studies with improvement to damaged kidney cells, and in human cell studies.,
A prospective study with a large human cohort found that higher plasma 25(OH)D levels were associated with a statistically significantly lower risk of RCC in men and women. Additionally, research on the circulating vitamin D-binding protein (DBP) suggests a strong protective association observed between higher circulating DBP concentration and renal cancer risk.
Suggested dose: Suggested dose is that sufficient to raise vitamin D blood levels to >40 ng/mL, which may require 5000 IU per day or more.